Pharmacokinetics of nilotinib in imatinib-resistant/intolerant chronic myeloid leukemia patients on hemodialysis for chronic renal failure

MeSH terms

• Aged
• Antineoplastic Agents / administration & dosage
• Antineoplastic Agents / adverse effects
• Antineoplastic Agents / blood
• Antineoplastic Agents / pharmacokinetics*
• Antineoplastic Agents / therapeutic use
• Benzamides
• Diabetic Nephropathies / therapy
• Drug Resistance, Neoplasm
• Female
• Gastrointestinal Hemorrhage / chemically induced
• Humans
• Imatinib Mesylate
• Kidney Failure, Chronic / complications
• Kidney Failure, Chronic / metabolism
• Kidney Failure, Chronic / therapy*
• Leukemia, Myeloid, Chronic-Phase / complications
• Leukemia, Myeloid, Chronic-Phase / drug therapy*
• Lung Diseases, Interstitial / chemically induced
• Male
• Middle Aged
• Nausea / chemically induced
• Piperazines / adverse effects
• Piperazines / blood
• Piperazines / pharmacology
• Piperazines / therapeutic use
• Polycystic Kidney Diseases / complications
• Protein Kinase Inhibitors / administration & dosage
• Protein Kinase Inhibitors / adverse effects
• Protein Kinase Inhibitors / pharmacokinetics*
• Protein Kinase Inhibitors / therapeutic use
• Pyrimidines / administration & dosage
• Pyrimidines / adverse effects
• Pyrimidines / blood
• Pyrimidines / pharmacokinetics*
• Pyrimidines / pharmacology
• Pyrimidines / therapeutic use
• Renal Dialysis*